Company Update: Baxter International Inc (NYSE:BAX) – UPDATE 1-Baxter’s blood disorder drug gets FDA approval (Oct 24)

[Reuters] – Eloctate is approved to treat congenital hemophilia A, not acquired hemophilia A) Oct 24 (Reuters) – Drugmaker Baxter International Inc said the U.S. Food and Drug Administration had approved its drug . . . → Read More: Company Update: Baxter International Inc (NYSE:BAX) – UPDATE 1-Baxter’s blood disorder drug gets FDA approval (Oct 24) Similar Articles: Stock Update (NYSE:BAX): FDA Approves Baxter’s OBIZUR [Antihemophilic Factor (Recombinant), Porcine Sequence], for Acquired Hemophilia A Stock Update (NYSE:BAX): FDA Approves Baxter’s RIXUBIS [Coagulation Factor IX (Recombinant)] for Treatment of Children with Hemophilia B Market Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen wins U.S. approval of long acting multiple sclerosis drug